29677-65-4 Usage
Uses
Used in Heavy Metal Poisoning Treatment:
2-(carboxymethylsulfanylcarbothioylamino)acetic acid is used as a chelating agent for the treatment of heavy metal poisoning. It binds to heavy metals, such as lead, mercury, and arsenic, facilitating their safe elimination from the body and reducing the toxic effects of these metals on vital organs.
Used in Kidney Stone Prevention for Cystinuria Patients:
In the medical field, 2-(carboxymethylsulfanylcarbothioylamino)acetic acid is used as a preventive measure for kidney stones in patients with cystinuria. By binding to cysteine and other sulfhydryl-containing compounds, it helps to reduce their concentration in the urine, thereby decreasing the risk of stone formation.
Used in Wilson's Disease Management:
2-(carboxymethylsulfanylcarbothioylamino)acetic acid is employed as a therapeutic agent in the management of Wilson's disease, a genetic disorder characterized by copper accumulation in the body. It aids in the mobilization and excretion of excess copper, thereby preventing the associated complications such as liver damage and neurological symptoms.
Used in Anti-inflammatory and Antioxidant Applications:
2-(carboxymethylsulfanylcarbothioylamino)acetic acid is being studied for its potential anti-inflammatory and antioxidant properties. It may have therapeutic applications in treating conditions like rheumatoid arthritis and cardiovascular disease, where inflammation and oxidative stress play significant roles in disease progression.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(carboxymethylsulfanylcarbothioylamino)acetic acid is used as an active pharmaceutical ingredient in the development of drugs targeting heavy metal poisoning, kidney stone prevention, and Wilson's disease management. Its unique chelating properties and potential therapeutic effects make it a valuable compound for drug discovery and development.
Used in Research and Development:
2-(carboxymethylsulfanylcarbothioylamino)acetic acid is utilized in research and development for exploring its potential applications in various fields, including medicine, environmental science, and materials science. Its ability to bind to heavy metals and sulfhydryl groups makes it an interesting candidate for the development of new technologies and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 29677-65-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,6,7 and 7 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 29677-65:
(7*2)+(6*9)+(5*6)+(4*7)+(3*7)+(2*6)+(1*5)=164
164 % 10 = 4
So 29677-65-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H7NO4S2/c7-3(8)1-6-5(11)12-2-4(9)10/h1-2H2,(H,6,11)(H,7,8)(H,9,10)
29677-65-4Relevant academic research and scientific papers
5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl)alkancarboxylic Acids as Antimicrobial Agents: Synthesis, biological evaluation, and molecular docking studies
Ciric, Ana,Geronikaki, Athina,Glamoclija, Jasmina,Horishny, Volodymyr,Kartsev, Victor,Matiychuk, Vasyl,Petrou, Anthi,Sokovic, Marina
, (2020/04/29)
Background: Infectious diseases symbolize a global consequential strain on public health security and impact on the socio-economic stability all over the world. The increasing resistance to the current antimicrobial treatment has resulted in crucial need for the discovery and development of novel entity for the infectious treatment with different modes of action that could target both sensitive and resistant strains. Methods: Compounds were synthesized using classical methods of organic synthesis. Results: All 20 synthesized compounds showed antibacterial activity against eight Gram-positive and Gram-negative bacterial species. It should be mentioned that all compounds exhibited better antibacterial potency than ampicillin against all bacteria tested. Furthermore, 18 compounds appeared to be more potent than streptomycin against Staphylococcus aureus, Enterobacter cloacae, Pseudomonas aeruginosa, Listeria monocytogenes, and Escherichia coli. Three the most active compounds 4h, 5b, and 5g appeared to be more potent against MRSA than ampicillin, while streptomycin did not show any bactericidal activity. All three compounds displayed better activity also against resistant strains P. aeruginosa and E. coli than ampicillin. Furthermore, all compounds were able to inhibit biofilm formation 2- to 4-times more than both reference drugs. Compounds were evaluated also for their antifungal activity against eight species. The evaluation revealed that all compounds exhibited antifungal activity better than the reference drugs bifonazole and ketoconazole. Molecular docking studies on antibacterial and antifungal targets were performed in order to elucidate the mechanism of antibacterial activity of synthesized compounds. Conclusion: All tested compounds showed good antibacterial and antifungal activity better than that of reference drugs and three the most active compounds could consider as lead compounds for the development of new more potent agents.
